C

동화약품

000020KOSPI의약품 제조업

53.0 / 100

Reference Date: 2026-07-24

Financial Score15.5 / 40
News Sentiment17.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Slightly up 1.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongwha Pharm operates in pharmaceuticals, medical device manufacturing and sales, and other financial services. In 2023, sales increased by 6.78% to 496,394 million won compared to the previous year, but operating profit fell by 98.09%. Key subsidiaries include Medissei (medical device manufacturer), TS Care (Vietnam-based pharmaceutical distribution chain), and Dongwha Kripton (venture investment firm).

Number of Employees

838people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
36.49Industry Average 11.230.0Point

3.2x industry avg (risky)

PBR
0.35Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE
0.96Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
9.44Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲17.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.9% (declining, 3yr)

Detailed News Sentiment

33 totalPositive 19Neutral 11Negative 3Average Sentiment Score 70.2

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 5,020Won52-week high 6,90052-week low 4,740
1-month return3.0Point

1m 1.01% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0